

Living Research



Currently enrolling studies at The Neurological Institute, Research Department

Fall 2011

Multiple Sclerosis Research



Multiple Sclerosis A study to evaluate the efficacy and safety of Ocrelizumab in comparison to Rebif in patients with RRMS

- 18-55 years old
- Diagnosed with RRMS
- At least 2 documented clinical attacks within last 2 years prior to screening, or 1 relapses in the year prior to screening



Multiple Sclerosis A long-term observational study monitoring safety in patients with MS newly started with fingolimod.

- Patient have been prescribed fingolimod treatment (Gilenya) but have not initiated treatment

Multiple Sclerosis A study of the efficacy and safety of Teriflunomide in RRMS patients who are treated with interferon-beta

- 18 – 55 years old
- Must be currently treated with interferon-beta (INF- β)
- 1 relapse within the past 12 months

Multiple Sclerosis A study to evaluate the efficacy and safety of two year treatment with teriflunomide in patients with a first clinical episode suggestive of MS

- 18-55 years old
- 1st onset of MS symptoms, occurring within 30 days, such as optic neuritis, spinal cord syndrome, brainstem/celebellar syndromes

Multiple Sclerosis A study to evaluate the safety and efficacy of oral Dalfampridine Extended Release tablets in MS patients

- 18-70 years old
- Diagnosed with MS
- Must be able to complete a 25 foot walking test

Parkinson's Disease Research



Alzheimer's Disease: A study on the effects of cognitive performance, safety and tolerability of SAR110894D in patients with mild to moderate Alzheimer's Disease.

- Mild to moderate Alzheimer's Disease
- On stable dose of donepezil (Aricept) 5 or 10 mg daily for at least 3 months

Parkinson's Disease A study to evaluate the efficacy and safety of praladenant in subjects with moderate to severe Parkinson's

- ≥ 30 to ≤ 85 years of age
- Diagnosis of idiopathic PD
- Must be on a stable dose of L-dopa for approximately 2 or more years

Parkinson's Disease A study to evaluate the efficacy and safety of praladenant in subject with early Parkinson's

- ≥ 30 to ≤ 85 years of age
- Diagnosis of idiopathic PD
- Can't be on L-dopa or dopamine agonist



Questions can be submitted to the Research Department by email: research@neuro-institute.com